Survival in heart failure
Introduction
- Heart failure (HF) is an enormous public health burden with 300,000 new deaths each year and a prevalence of 6.5 million people in the United States1.
- There is large variability in HF prognosis2, and there is a need for a broader systemic approach to identify novel circulating markers of HF progression.
- One of the most robust and validated models for mortality prediction in HF patients is the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Score3.
- Additionally, the use of N-Terminal pro-B-Type Natriuretic Peptide (NTproBNP) has been shown to be valuable in prognosis prediction4.
- It is uncertain if the plasma proteome is a better prediction tool for the course of HF compared to the clinical risk score MAGGIC and NTproBNP.
More posters
PosterLatest research shows benefit of non-invasive, high-plex protein profiling for liver disease
Learn about using high-plex, aptamer-based protein profiling for NASH research through these three SomaLogic assets. Watch one webinar and download two posters that each highlight NASH research.
PosterProteomic Indicators of Metabolic Health in Diabetes and Social Deprivation
Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives. Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 11 cardiometabolic SomaSignalTM Tests (SST)
PosterHeritability, pQTLs, and environmental influence on proteins involved in age, cardiovascular risk, and glucose tolerance using the SomaScan® Assay
Protein quantitative trait locus (“pQTL”) studies identify genetic variants that are statistically associated with protein levels. Results from the growing number of pQTL studies can be combined with genome-wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.